Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 613

1.

Is post-transplant cyclophosphamide a true game-changer in allogeneic transplantation: The struggle to unlearn.

Jones RJ.

Best Pract Res Clin Haematol. 2019 Dec;32(4):101112. doi: 10.1016/j.beha.2019.101112. Epub 2019 Oct 20. Review.

PMID:
31779984
2.

Allogeneic Haploidentical Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide in Chronic Lymphocytic Leukemia.

Paul S, Tsai HL, Lowery P, Fuchs EJ, Luznik L, Bolaños-Meade J, Swinnen LJ, Shanbhag S, Wagner-Johnston N, Varadhan R, Ambinder RF, Jones RJ, Gladstone DE.

Biol Blood Marrow Transplant. 2019 Nov 12. pii: S1083-8791(19)30748-7. doi: 10.1016/j.bbmt.2019.11.008. [Epub ahead of print]

PMID:
31730920
3.

Environmental pollutant induced cellular injury is reflected in exosomes from placental explants.

Sheller-Miller S, Radnaa E, Arita Y, Getahun D, Jones RJ, Peltier MR, Menon R.

Placenta. 2019 Oct 17;89:42-49. doi: 10.1016/j.placenta.2019.10.008. [Epub ahead of print]

PMID:
31675489
4.

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, Brawley CD, Calvert J, Chowdhury S, Cook A, Cross W, Dearnaley DP, Douis H, Gilbert D, Gillessen S, Jones RJ, Langley RE, MacNair A, Malik Z, Mason MD, Matheson D, Millman R, Parker CC, Ritchie AWS, Rush H, Russell JM, Brown J, Beesley S, Birtle A, Capaldi L, Gale J, Gibbs S, Lydon A, Nikapota A, Omlin A, O'Sullivan JM, Parikh O, Protheroe A, Rudman S, Srihari NN, Simms M, Tanguay JS, Tolan S, Wagstaff J, Wallace J, Wylie J, Zarkar A, Sydes MR, Parmar MKB, James ND.

Ann Oncol. 2019 Sep 27. pii: mdz396. doi: 10.1093/annonc/mdz396. [Epub ahead of print]

PMID:
31560068
5.

A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.

Pratz KW, Rudek MA, Smith BD, Karp J, Gojo I, Dezern A, Jones RJ, Greer J, Gocke C, Baer MR, Duong VH, Rosner G, Zahurak M, Wright JJ, Emadi A, Levis M; ETCTN-8922 study team.

Biol Blood Marrow Transplant. 2019 Sep 21. pii: S1083-8791(19)30634-2. doi: 10.1016/j.bbmt.2019.09.023. [Epub ahead of print]

PMID:
31550496
6.

Does the triceps-on approach affect alignment in total elbow arthroplasty? A cadaveric study.

King A, Evans JP, Booker SJ, Beazley JC, Jones RJ, Thomas WJ, Smith C.

Shoulder Elbow. 2019 Oct;11(5):372-377. Epub 2018 May 25.

PMID:
31534487
7.

Scanning Electrochemical Flow Cell with Online Mass Spectroscopy for Accelerated Screening of Carbon Dioxide Reduction Electrocatalysts.

Lai Y, Jones RJR, Wang Y, Zhou L, Gregoire JM.

ACS Comb Sci. 2019 Oct 14;21(10):692-704. doi: 10.1021/acscombsci.9b00130. Epub 2019 Sep 25.

PMID:
31525292
8.

Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70.

Imus PH, Tsai HL, Luznik L, Fuchs EJ, Huff CA, Gladstone DE, Lowery P, Ambinder RF, Borrello IM, Swinnen LJ, Wagner-Johnston N, Gocke CB, Ali SA, Bolaños-Meade FJ, Varadhan R, Jones RJ.

Blood Adv. 2019 Sep 10;3(17):2608-2616. doi: 10.1182/bloodadvances.2019000155.

9.

Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.

Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, Attard G, Chowdhury S, Cross WR, Dearnaley DP, Brawley CD, Gilson C, Ingleby F, Gillessen S, Aebersold DM, Jones RJ, Matheson D, Millman R, Mason MD, Ritchie AWS, Russell M, Douis H, Parmar MKB, Sydes MR, Clarke NW; STAMPEDE Investigators.

Eur Urol. 2019 Dec;76(6):719-728. doi: 10.1016/j.eururo.2019.08.006. Epub 2019 Aug 23.

PMID:
31447077
10.

Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation.

Imus PH, Blackford AL, Bettinotti M, Luznik L, Fuchs EJ, Huff CA, Gladstone DE, Ambinder RF, Borrello IM, Fuchs RJ, Swinnen LJ, Wagner-Johnston N, Gocke CB, Ali SA, Bolaños-Meade FJ, Jones RJ, Dezern AE.

Biol Blood Marrow Transplant. 2019 Dec;25(12):2431-2437. doi: 10.1016/j.bbmt.2019.07.027. Epub 2019 Aug 5.

PMID:
31394272
11.

Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.

Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Cyktor J, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, Forman SJ, Porter D, Arce-Lara C, Shaughnessy P, Sproat L, Hashmi SK, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2160-2166. doi: 10.1016/j.bbmt.2019.06.033. Epub 2019 Jul 4.

PMID:
31279752
12.

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study.

Attard G, Merseburger AS, Arlt W, Sternberg CN, Feyerabend S, Berruti A, Joniau S, Géczi L, Lefresne F, Lahaye M, Shelby FN, Pissart G, Chua S, Jones RJ, Tombal B.

JAMA Oncol. 2019 Jun 27. doi: 10.1001/jamaoncol.2019.1011. [Epub ahead of print] Erratum in: JAMA Oncol. 2019 Aug 1;5(8):1232.

13.

Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma?

Shanbhag S, Wagner-Johnston N, Ambinder RF, Jones RJ.

Curr Oncol Rep. 2019 Jun 10;21(7):65. doi: 10.1007/s11912-019-0809-z. Review.

PMID:
31183579
14.

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.

Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR, Cook A, Cross WR, Dearnaley DP, Gale J, Gibbs S, Graham JD, Hughes R, Jones RJ, Laing R, Mason MD, Matheson D, McLaren DB, Millman R, O'Sullivan JM, Parikh O, Parker CC, Peedell C, Protheroe A, Ritchie AWS, Robinson A, Russell JM, Simms MS, Srihari NN, Srinivasan R, Staffurth JN, Sundar S, Thalmann GN, Tolan S, Tran ATH, Tsang D, Wagstaff J, James ND, Sculpher MJ.

Eur Urol Oncol. 2018 Dec;1(6):449-458. doi: 10.1016/j.euo.2018.06.004. Epub 2018 Sep 14.

15.

Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance.

Karantanos T, Jones RJ.

Adv Exp Med Biol. 2019;1139:153-169. doi: 10.1007/978-3-030-14366-4_9. Review.

PMID:
31134500
16.

FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?

Levis MJ, Chen YB, Hamadani M, Horowitz MM, Jones RJ; Blood and Marrow Transplant Clinical Trials Network.

J Clin Oncol. 2019 Jul 1;37(19):1604-1607. doi: 10.1200/JCO.19.00321. Epub 2019 Apr 29. No abstract available.

17.

Family and friends: Supporting oral care in care homes.

Jones RJ, Johnson IG, Morgan MZ.

Gerodontology. 2019 Sep;36(3):258-266. doi: 10.1111/ger.12404. Epub 2019 Apr 17.

PMID:
30994206
18.

Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment.

Su M, Chang YT, Hernandez D, Jones RJ, Ghiaur G.

J Cell Mol Med. 2019 Jun;23(6):4111-4117. doi: 10.1111/jcmm.14298. Epub 2019 Mar 28.

19.

Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.

Chang YT, Hernandez D, Alonso S, Gao M, Su M, Ghiaur G, Levis MJ, Jones RJ.

Blood Adv. 2019 Mar 26;3(6):908-916. doi: 10.1182/bloodadvances.2018022921.

20.

Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.

Bolaños-Meade J, Cooke KR, Gamper CJ, Ali SA, Ambinder RF, Borrello IM, Fuchs EJ, Gladstone DE, Gocke CB, Huff CA, Luznik L, Swinnen LJ, Symons HJ, Terezakis SA, Wagner-Johnston N, Jones RJ, Brodsky RA.

Lancet Haematol. 2019 Apr;6(4):e183-e193. doi: 10.1016/S2352-3026(19)30031-6. Epub 2019 Mar 14. Erratum in: Lancet Haematol. 2019 May;6(5):e238.

PMID:
30878319
21.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.

Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7.

PMID:
30824040
22.

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.

Zhuang J, Shirazi F, Singh RK, Kuiatse I, Wang H, Lee HC, Berkova Z, Berger A, Hyer M, Chattopadhyay N, Syed S, Shi JQ, Yu J, Shinde V, Tirrell S, Jones RJ, Wang Z, Davis RE, Orlowski RZ.

Blood. 2019 Apr 4;133(14):1572-1584. doi: 10.1182/blood-2018-06-859686. Epub 2019 Feb 8.

PMID:
30737236
23.

R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma.

Messmer M, Tsai HL, Varadhan R, Swinnen LJ, Jones RJ, Ambinder RF, Shanbhag SP, Borowitz MJ, Wagner-Johnston N.

Leuk Lymphoma. 2019 May;60(5):1261-1265. doi: 10.1080/10428194.2018.1519812. Epub 2019 Jan 18.

PMID:
30656983
24.

Reactor design and integration with product detection to accelerate screening of electrocatalysts for carbon dioxide reduction.

Jones RJR, Wang Y, Lai Y, Shinde A, Gregoire JM.

Rev Sci Instrum. 2018 Dec;89(12):124102. doi: 10.1063/1.5049704.

PMID:
30599585
25.

Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide.

McCurdy SR, Kanakry CG, Tsai HL, Gojo I, Smith BD, Gladstone DE, Bolaños-Meade J, Borrello I, Matsui WH, Swinnen LJ, Huff CA, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1128-1135. doi: 10.1016/j.bbmt.2018.12.767. Epub 2018 Dec 30.

26.

3D Molecular Cytology of Hop (Humulus lupulus) Meiotic Chromosomes Reveals Non-disomic Pairing and Segregation, Aneuploidy, and Genomic Structural Variation.

Easterling KA, Pitra NJ, Jones RJ, Lopes LG, Aquino JR, Zhang D, Matthews PD, Bass HW.

Front Plant Sci. 2018 Nov 1;9:1501. doi: 10.3389/fpls.2018.01501. eCollection 2018.

27.

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators.

Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21.

28.

Sediment characteristics influence the fertilisation success of the corals Acropora tenuis and Acropora millepora.

Ricardo GF, Jones RJ, Clode PL, Humanes A, Giofre N, Negri AP.

Mar Pollut Bull. 2018 Oct;135:941-953. doi: 10.1016/j.marpolbul.2018.08.001. Epub 2018 Aug 16.

29.

Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.

Dobbin SJH, Cameron AC, Petrie MC, Jones RJ, Touyz RM, Lang NN.

Heart. 2018 Dec;104(24):1995-2002. doi: 10.1136/heartjnl-2018-313726. Epub 2018 Sep 18. Review.

30.

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.

Schoch LK, Cooke KR, Wagner-Johnston ND, Gojo I, Swinnen LJ, Imus P, Fuchs EJ, Levis M, Ambinder RF, Jones RJ, Gladstone DE.

Blood Adv. 2018 Sep 11;2(17):2226-2229. doi: 10.1182/bloodadvances.2018019208.

31.

Should an HLA-matched donor still be considered the perfect donor?

Jones RJ, Horowitz MM.

Lancet Haematol. 2018 Sep;5(9):e388-e390. doi: 10.1016/S2352-3026(18)30119-4. No abstract available.

PMID:
30172342
32.

Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.

Ni H, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Hitoshi Y, Ansell SM, Treon SP, Thomas SK, Lee HC, Wang Z, Davis RE, Orlowski RZ.

Clin Cancer Res. 2018 Dec 15;24(24):6408-6420. doi: 10.1158/1078-0432.CCR-17-3265. Epub 2018 Aug 20.

PMID:
30126942
33.

Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment.

DeZern AE, Jones RJ, Brodsky RA.

Biol Blood Marrow Transplant. 2018 Dec;24(12):e26-e30. doi: 10.1016/j.bbmt.2018.07.032. Epub 2018 Jul 26.

34.

Clinical skills of a new foundation dentist: the experience of dental foundation educational supervisors.

Jones RJ, Cowpe JG, Bullock AD, Gilmour ASM.

Br Dent J. 2018 Jul 27;225(2):177-186. doi: 10.1038/sj.bdj.2018.536. No abstract available.

PMID:
30050194
35.

Clinical skills of a new foundation dentist: the expectations of dental foundation education supervisors.

Gilmour ASM, Jones RJ, Cowpe JG, Bullock AD.

Br Dent J. 2018 Jul 13;225(1):73-80. doi: 10.1038/sj.bdj.2018.526. Epub 2018 Jul 6. No abstract available.

PMID:
29977021
36.

Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes.

McCurdy SR, Muth ST, Tsai HL, Symons HJ, Huff CA, Matsui WH, Borrello I, Gladstone DE, Swinnen LJ, Cooke KR, Brodsky RA, Bolaños-Meade J, Ambinder RF, Varadhan R, Luznik L, Jones RJ, Bettinot MP, Fuchs EJ.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2056-2064. doi: 10.1016/j.bbmt.2018.06.004. Epub 2018 Jun 15.

37.

Corrigendum to "Settlement patterns of the coral Acropora millepora on sediment-laden surfaces" [Sci. Total Environ. 609 (2017) 277-288].

Ricardo GF, Jones RJ, Nordborg M, Negri AP.

Sci Total Environ. 2018 Nov 1;640-641:116. doi: 10.1016/j.scitotenv.2018.05.219. Epub 2018 May 30. No abstract available.

PMID:
29859428
38.

Counterpoint: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Abiraterone.

Jones RJ.

Oncology (Williston Park). 2018 May 15;32(5):223, 226-7, 247. No abstract available.

39.

Extending surgeon response times in tier 2 traumas does not adversely affect patient outcomes.

Zimmerman SA, Reed CS, Reed AN, Jones RJ, Chard A, Reed DN Jr.

J Surg Res. 2018 Jun;226:24-30. doi: 10.1016/j.jss.2017.12.037. Epub 2018 Feb 10.

PMID:
29661285
40.

Dual-comb spectroscopy of laser-induced plasmas.

Bergevin J, Wu TH, Yeak J, Brumfield BE, Harilal SS, Phillips MC, Jones RJ.

Nat Commun. 2018 Mar 28;9(1):1273. doi: 10.1038/s41467-018-03703-0.

41.

Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.

Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK, Lu J, Qian Y, Raina K, Coleman KG, Crews CM, Li B, Wang H, Hailemichael Y, Thomas SK, Wang Z, Davis RE, Orlowski RZ.

Leukemia. 2018 Oct;32(10):2224-2239. doi: 10.1038/s41375-018-0044-x. Epub 2018 Mar 27.

42.

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.

Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, Bolaños-Meade J, Fuchs EJ, Wagner-Johnston N, Swinnen LJ, Huff CA, Matsui WH, Gladstone DE, McCurdy SR, Borrello I, Gocke CB, Shanbhag S, Cooke KR, Ali SA, Brodsky RA, DeZern AE, Luznik L, Jones RJ, Ambinder RF.

Biol Blood Marrow Transplant. 2018 May;24(5):1099-1102. doi: 10.1016/j.bbmt.2018.02.005. Epub 2018 Feb 13.

43.

Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.

Kasamon YL, Fuchs EJ, Zahurak M, Rosner GL, Symons HJ, Gladstone DE, Huff CA, Swinnen LJ, Brodsky RA, Matsui WH, Borrello I, Shanbhag S, Cooke KR, Ambinder RF, Luznik L, Bolaños-Meade J, Jones RJ.

Biol Blood Marrow Transplant. 2018 May;24(5):1022-1028. doi: 10.1016/j.bbmt.2018.01.011. Epub 2018 Jan 17.

44.

Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.

Pasquini MC, Logan B, Jones RJ, Alousi AM, Appelbaum FR, Bolaños-Meade J, Flowers MED, Giralt S, Horowitz MM, Jacobsohn D, Koreth J, Levine JE, Luznik L, Maziarz R, Mendizabal A, Pavletic S, Perales MA, Porter D, Reshef R, Weisdorf D, Antin JH.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1274-1280. doi: 10.1016/j.bbmt.2018.01.002. Epub 2018 Jan 8.

45.

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, Levis MJ, Gladstone DE, Huff CA, Swinnen LJ, Matsui WH, Borrello I, Brodsky RA, Jones RJ, Luznik L.

Blood Adv. 2017;1(4):288-292. doi: 10.1182/bloodadvances.2016002766. Epub 2017 Jan 6.

46.

Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients.

Schoch LK, Asiama A, Zahurak M, Shanbhag S, Hurtt J, Sawyer K, Swinnen LJ, Wagner-Johnston N, Jones RJ, Ambinder RF, Gladstone DE.

Cancer Chemother Pharmacol. 2018 Feb;81(2):347-354. doi: 10.1007/s00280-017-3499-y. Epub 2017 Dec 13.

PMID:
29234922
47.

Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes.

Purushothaman A, Bandari SK, Chandrashekar DS, Jones RJ, Lee HC, Weber DM, Orlowski RZ.

Oncotarget. 2017 Aug 27;8(43):73723-73732. doi: 10.18632/oncotarget.20564. eCollection 2017 Sep 26.

48.

Immune checkpoint inhibitors in renal cell carcinoma.

Ross K, Jones RJ.

Clin Sci (Lond). 2017 Oct 27;131(21):2627-2642. doi: 10.1042/CS20160894. Print 2017 Nov 1. Review.

49.

Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.

McCurdy SR, Kanakry CG, Tsai HL, Kasamon YL, Showel MM, Bolaños-Meade J, Huff CA, Borrello I, Matsui WH, Brodsky RA, Ambinder RF, Bettinotti MP, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Biol Blood Marrow Transplant. 2018 Feb;24(2):343-352. doi: 10.1016/j.bbmt.2017.10.023. Epub 2017 Oct 18.

50.

Y-Chromosome haplotypes reveal relationships between populations of the Arabian Peninsula, North Africa and South Asia.

Jones RJ, Tay GK, Mawart A, Alsafar H.

Ann Hum Biol. 2017 Dec;44(8):738-746. doi: 10.1080/03014460.2017.1384508. Epub 2017 Oct 16.

PMID:
28948851

Supplemental Content

Loading ...
Support Center